{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:14:47Z","timestamp":1791756887281,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Berthiaume Institute for Precision Health at the University of Notre Dame","award":["Substance Abuse Fund"],"award-info":[{"award-number":["Substance Abuse Fund"]}]},{"name":"Berthiaume Institute for Precision Health at the University of Notre Dame","award":["Substance Abuse Fund"],"award-info":[{"award-number":["Substance Abuse Fund"]}]},{"name":"Berthiaume Institute for Precision Health at the University of Notre Dame","award":["Substance Abuse Fund"],"award-info":[{"award-number":["Substance Abuse Fund"]}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["UL1TR002529"],"award-info":[{"award-number":["UL1TR002529"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["IIP-2016516"],"award-info":[{"award-number":["IIP-2016516"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["IIP-2016516"],"award-info":[{"award-number":["IIP-2016516"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["IIP-2016516"],"award-info":[{"award-number":["IIP-2016516"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Shifts in the US drug supply, including the proliferation of synthetic opioids and emergence of xylazine, have contributed to the worsening toll of the overdose epidemic. Drug checking services offer a critical intervention to promote agency among people who use drugs (PWUD) to reduce overdose risk. Current drug checking methods can be enhanced to contribute to supply-level monitoring in the USA, overcoming the selection bias associated with existing supply monitoring efforts and informing public health interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As a group of analytical chemists, public health researchers, evaluators, and harm reductionists, we used a semi-structured guide to facilitate discussion of four different approaches for syringe service programs (SSPs) to offer drug checking services for supply-level monitoring. Using thematic analysis, we identified four key principles that SSPs should consider when implementing drug checking programs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A number of analytical methods exist for drug checking to contribute to supply-level monitoring. While there is likely not a one-size-fits-all approach, SSPs should prioritize methods that can (1) provide immediate utility to PWUD, (2) integrate seamlessly into existing workflows, (3) balance individual- and population-level data needs, and (4) attend to legal concerns for implementation and dissemination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Enhancing drug checking methods for supply-level monitoring has the potential to detect emerging threats in the drug supply and reduce the toll of the worsening overdose epidemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-023-00924-5","type":"journal-article","created":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:01:21Z","timestamp":1705158081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Enhancing drug checking services for supply monitoring: perspectives on implementation in syringe service programs in the USA"],"prefix":"10.1186","volume":"21","author":[{"given":"Kyle J.","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather D.","family":"Whitehead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn A.","family":"Hasenstab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen L.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saira","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"key":"924_CR1","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jama.2022.12240","volume":"328","author":"M Kariisa","year":"2022","unstructured":"Kariisa M, Seth P, Jones CM. Increases in disparities in US drug overdose deaths by race and ethnicity: opportunities for clinicians and health systems. JAMA. 2022;328:421\u20132.","journal-title":"JAMA"},{"key":"924_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.annepidem.2022.11.007","volume":"77","author":"H Lee","year":"2023","unstructured":"Lee H, Singh GK. Estimating the impact of the COVID-19 pandemic on rising trends in drug overdose mortality in the United States, 2018\u20132021. Ann Epidemiol. 2023;77:85\u20139.","journal-title":"Ann Epidemiol"},{"key":"924_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.06.010","volume":"46","author":"D Ciccarone","year":"2017","unstructured":"Ciccarone D. Fentanyl in the US heroin supply: a rapidly changing risk environment. Int J Drug Policy. 2017;46:107\u201311.","journal-title":"Int J Drug Policy"},{"key":"924_CR4","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.15585\/mmwr.mm7150a2","volume":"71","author":"LJ Tanz","year":"2022","unstructured":"Tanz LJ, Dinwiddie AT, Mattson CL, O\u2019Donnell J, Davis NL. Drug overdose deaths among persons aged 10\u201319 years\u2014United States, July 2019\u2013December 2021. Morb Mortal Wkly Rep. 2022;71:1576\u201382.","journal-title":"Morb Mortal Wkly Rep"},{"key":"924_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/phn.13193","volume":"40","author":"JJ Palamar","year":"2023","unstructured":"Palamar JJ. Awareness that cocaine can contain fentanyl among nightclub and festival attendees in New York City, 2018\u20132022. Public Health Nurs. 2023;40:1\u20136.","journal-title":"Public Health Nurs"},{"key":"924_CR6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1080\/10826084.2022.2120365","volume":"57","author":"S Arya","year":"2022","unstructured":"Arya S, Nagappala S, Krawczyk N, Gi Y, Meacham MC, Bunting AM. Fentanyl in pressed oxycodone pills: a qualitative analysis of online community experiences with an emerging drug trend. Subst Use Misuse. 2022;57:1940\u20135.","journal-title":"Subst Use Misuse"},{"key":"924_CR7","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, Wahbi R, Dye D, Goodman-Meza D, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380.","journal-title":"Drug Alcohol Depend"},{"key":"924_CR8","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: trends, concerns, and recommendations. Am J Public Health. 2022;112:1212\u20136.","journal-title":"Am J Public Health"},{"key":"924_CR9","doi-asserted-by":"publisher","first-page":"103169","DOI":"10.1016\/j.drugpo.2021.103169","volume":"93","author":"MK Laing","year":"2021","unstructured":"Laing MK, Ti L, Marmel A, Tobias S, Shapiro AM, Laing R, et al. An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: preliminary results from a community drug checking program using point-of-care and confirmatory methods. Int J Drug Policy. 2021;93:103169.","journal-title":"Int J Drug Policy"},{"key":"924_CR10","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.15585\/mmwr.mm7034a4","volume":"70","author":"K Aldy","year":"2021","unstructured":"Aldy K, Mustaquim D, Campleman S, Meyn A, Abston S, Krotulski A, et al. Illicit benzodiazepines detected in patients evaluated in emergency departments for suspected opioid overdose\u2014four states, October 6, 2020\u2013March 9, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1177\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"924_CR11","first-page":"222","volume":"84","author":"D Frank","year":"2022","unstructured":"Frank D, Krawczyk N, Arshonsky J, Bragg MA, Friedman SR, Bunting AM. Covid-19-related changes to drug-selling networks and their effects on people who use illicit opioids. J Stud Alcohol Drugs. 2022;84:222\u20139.","journal-title":"J Stud Alcohol Drugs"},{"key":"924_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1468-0009.12602","volume":"101","author":"M Cerd\u00e1","year":"2023","unstructured":"Cerd\u00e1 M, Krawczyk N, Keyes K. The future of the united states overdose crisis: challenges and opportunities. Milbank Q. 2023;101:1\u201329.","journal-title":"Milbank Q"},{"key":"924_CR13","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/aje\/kwab233","volume":"191","author":"N Dasgupta","year":"2022","unstructured":"Dasgupta N, Figgatt MC. Drug checking for novel insights into the unregulated drug supply. Am J Epidemiol. 2022;191:248\u201352.","journal-title":"Am J Epidemiol"},{"key":"924_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/YCO.0000000000000607","volume":"33","author":"JJ Palamar","year":"2020","unstructured":"Palamar JJ, Salomone A, Barratt MJ. Drug checking to detect fentanyl and new psychoactive substances. Curr Opin Psychiatry. 2020;33:301\u20135.","journal-title":"Curr Opin Psychiatry"},{"key":"924_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugpo.2018.10.001","volume":"62","author":"MK Laing","year":"2018","unstructured":"Laing MK, Tupper KW, Fairbairn N. Drug checking as a potential strategic overdose response in the fentanyl era. Int J Drug Policy. 2018;62:59\u201366.","journal-title":"Int J Drug Policy"},{"key":"924_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138.","journal-title":"Int J Drug Policy"},{"key":"924_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-022-00590-z","volume":"19","author":"JJ Carroll","year":"2022","unstructured":"Carroll JJ, Mackin S, Schmidt C, McKenzie M, Green TC. The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19. Harm Reduct J. 2022;19:1\u201313.","journal-title":"Harm Reduct J"},{"key":"924_CR18","doi-asserted-by":"publisher","first-page":"102900","DOI":"10.1016\/j.drugpo.2020.102900","volume":"84","author":"NP Weicker","year":"2020","unstructured":"Weicker NP, Owczarzak J, Urquhart G, Park JN, Rouhani S, Ling R, et al. Agency in the fentanyl era: exploring the utility of fentanyl test strips in an opaque drug market. Int J Drug Policy. 2020;84:102900.","journal-title":"Int J Drug Policy"},{"key":"924_CR19","doi-asserted-by":"publisher","first-page":"109425","DOI":"10.1016\/j.drugalcdep.2022.109425","volume":"234","author":"CS Davis","year":"2022","unstructured":"Davis CS, Lieberman AJ, O\u2019Kelley-Bangsberg M. Legality of drug checking equipment in the United States: a systematic legal analysis. Drug Alcohol Depend. 2022;234:109425.","journal-title":"Drug Alcohol Depend"},{"key":"924_CR20","doi-asserted-by":"publisher","first-page":"103196","DOI":"10.1016\/j.drugpo.2021.103196","volume":"94","author":"JN Park","year":"2021","unstructured":"Park JN, Frankel S, Morris M, Dieni O, Fahey-Morrison L, Luta M, et al. Evaluation of fentanyl test strip distribution in two Mid-Atlantic syringe services programs. Int J Drug Policy. 2021;94:103196.","journal-title":"Int J Drug Policy"},{"key":"924_CR21","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","volume":"117","author":"N Maghsoudi","year":"2022","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, Rammohan I, Ziegler C, Werb D, et al. Drug checking services for people who use drugs: a systematic review. Addiction. 2022;117:532\u201344.","journal-title":"Addiction"},{"key":"924_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12954-018-0252-8","volume":"15","author":"M Karamouzian","year":"2018","unstructured":"Karamouzian M, Dohoo C, Forsting S, McNeil R, Kerr T, Lysyshyn M. Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada. Harm Reduct J. 2018;15:46.","journal-title":"Harm Reduct J"},{"key":"924_CR23","doi-asserted-by":"publisher","first-page":"100475","DOI":"10.1016\/j.forc.2023.100475","volume":"33","author":"HD Whitehead","year":"2023","unstructured":"Whitehead HD, Hayes KL, Swartz JA, Prete E, Robison-Taylor L, Ellen Mackesy-Amiti M, et al. Validated method for the analysis of 22 illicit drugs and their metabolites via liquid chromatography tandem mass spectrometry (LC\u2013MS\/MS) in illicit drug samples collected in Chicago, IL. Forensic Chem. 2023;33:100475.","journal-title":"Forensic Chem"},{"key":"924_CR24","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074.","journal-title":"Drug Alcohol Depend Rep"},{"key":"924_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.drugalcdep.2018.10.017","volume":"194","author":"JL Glick","year":"2019","unstructured":"Glick JL, Christensen T, Nyeong Park J, McKenzie M, Green TC, Sherman SG. Stakeholder perspectives on implementing fentanyl drug checking: results from a multi-site study. Drug Alcohol Depend. 2019;194:527\u201332.","journal-title":"Drug Alcohol Depend"},{"key":"924_CR26","doi-asserted-by":"publisher","first-page":"102661","DOI":"10.1016\/j.drugpo.2020.102661","volume":"77","author":"TC Green","year":"2020","unstructured":"Green TC, Park JN, Gilbert M, McKenzie M, Struth E, Lucas R, et al. An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples. Int J Drug Policy. 2020;77:102661.","journal-title":"Int J Drug Policy"},{"key":"924_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12954-023-00764-3","volume":"20","author":"L Gozdzialski","year":"2023","unstructured":"Gozdzialski L, Wallace B, Hore D. Point-of-care community drug checking technologies: an insider look at the scientific principles and practical considerations. Harm Reduct J. 2023;20:39.","journal-title":"Harm Reduct J"},{"key":"924_CR28","doi-asserted-by":"publisher","first-page":"108006","DOI":"10.1016\/j.drugalcdep.2020.108006","volume":"212","author":"L Ti","year":"2020","unstructured":"Ti L, Tobias S, Lysyshyn M, Laing R, Nosova E, Choi J, et al. Detecting fentanyl using point-of-care drug checking technologies: a validation study. Drug Alcohol Depend. 2020;212:108006.","journal-title":"Drug Alcohol Depend"},{"key":"924_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12954-023-00902-x","volume":"20","author":"M Perri","year":"2023","unstructured":"Perri M, Khorasheh T, Poon D-O, Kaminski N, LeBlanc S, Mizon L, et al. A rapid review of current engagement strategies with people who use drugs in monitoring and reporting on substance use-related harms. Harm Reduct J. 2023;20:169.","journal-title":"Harm Reduct J"},{"key":"924_CR30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/CXA.0000000000000089","volume":"11","author":"S Tobias","year":"2020","unstructured":"Tobias S, Shapiro AM, Wu H, Ti L. Xylazine identified in the unregulated drug supply in British Columbia, Canada. Can J Addict. 2020;11:28\u201332.","journal-title":"Can J Addict"},{"key":"924_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12954-021-00546-9","volume":"18","author":"JM Bowles","year":"2021","unstructured":"Bowles JM, McDonald K, Maghsoudi N, Thompson H, Stefan C, Beriault DR, et al. Xylazine detected in unregulated opioids and drug administration equipment in Toronto, Canada: clinical and social implications. Harm Reduct J. 2021;18:104.","journal-title":"Harm Reduct J"},{"key":"924_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000507049","volume":"27","author":"F Betzler","year":"2021","unstructured":"Betzler F, Helbig J, Viohl L, Ernst F, Roediger L, Gutwinski S, et al. Drug checking and its potential impact on substance use. Eur Addict Res. 2021;27:25\u201332.","journal-title":"Eur Addict Res"},{"key":"924_CR33","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/dta.323","volume":"3","author":"TM Brunt","year":"2011","unstructured":"Brunt TM, Niesink RJM. The drug information and monitoring system (DIMS) in the Netherlands: implementation, results, and international comparison. Drug Test Anal. 2011;3:621\u201334.","journal-title":"Drug Test Anal"},{"key":"924_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/1556-4029.14318","volume":"65","author":"TLE Lockwood","year":"2020","unstructured":"Lockwood TLE, Leong TX, Bliese SL, Helmke A, Richard A, Merga G, et al. idPAD: paper analytical device for presumptive identification of illicit drugs. J Forensic Sci. 2020;65:1289\u201397.","journal-title":"J Forensic Sci"},{"key":"924_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s43586-023-00197-z","volume":"3","author":"KL Hayes","year":"2023","unstructured":"Hayes KL, Lieberman M. Considerations for the design and implementation of point-of-care technology for use in low- and middle-income countries. Nat Rev Methods Primers. 2023;3:8\u20139.","journal-title":"Nat Rev Methods Primers"},{"key":"924_CR36","volume-title":"Development of analytical methods for highly selective and sensitive analysis of compounds relevant to human health and the environment","author":"HD Whitehead","year":"2023","unstructured":"Whitehead HD. Development of analytical methods for highly selective and sensitive analysis of compounds relevant to human health and the environment. Notre Dame: University of Notre Dame; 2023."},{"key":"924_CR37","doi-asserted-by":"publisher","first-page":"103825","DOI":"10.1016\/j.drugpo.2022.103825","volume":"109","author":"EJ Austin","year":"2022","unstructured":"Austin EJ, Corcorran MA, Briggs ES, Frost MC, Behrends CN, Juarez AM, et al. Barriers to engaging people who use drugs in harm reduction services during the COVID-19 pandemic: a mixed methods study of syringe services program perspectives. Int J Drug Policy. 2022;109:103825.","journal-title":"Int J Drug Policy"},{"key":"924_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-11-19","volume":"11","author":"A Kimerg\u00e5rd","year":"2014","unstructured":"Kimerg\u00e5rd A, McVeigh J. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study. Harm Reduct J. 2014;11:1\u201313.","journal-title":"Harm Reduct J"},{"key":"924_CR39","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1080\/07853890.2022.2121418","volume":"54","author":"ST Allen","year":"2022","unstructured":"Allen ST, O\u2019Rourke A, Johnson JA, Cheatom C, Zhang Y, Delise B, et al. Evaluating the impact of naloxone dispensation at public health vending machines in Clark County, Nevada. Ann Med. 2022;54:2692\u2013700.","journal-title":"Ann Med"},{"key":"924_CR40","doi-asserted-by":"publisher","first-page":"108722","DOI":"10.1016\/j.drugalcdep.2021.108722","volume":"224","author":"T-LE Lockwood","year":"2021","unstructured":"Lockwood T-LE, Huynh P, Richard A, Sightes E, Bailey K, Ray B, et al. Community overdose surveillance: comparing substances collected from the death scene investigation to toxicology results. Drug Alcohol Depend. 2021;224:108722.","journal-title":"Drug Alcohol Depend"},{"key":"924_CR41","doi-asserted-by":"publisher","first-page":"103467","DOI":"10.1016\/j.drugpo.2021.103467","volume":"99","author":"SE Duhart Clarke","year":"2022","unstructured":"Duhart Clarke SE, Kral AH, Zibbell JE. Consuming illicit opioids during a drug overdose epidemic: Illicit fentanyls, drug discernment, and the radical transformation of the illicit opioid market. Int J Drug Policy. 2022;99:103467.","journal-title":"Int J Drug Policy"},{"key":"924_CR42","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","volume":"70","author":"J O\u2019Donnell","year":"2021","unstructured":"O\u2019Donnell J, Tanz LJ, Gladden RM, Davis NL, Bitting J. Trends in and characteristics of drug overdose deaths involving illicitly manufactured fentanyls\u2014United States, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70:1740\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"924_CR43","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/10826084.2018.1552303","volume":"54","author":"K McLean","year":"2019","unstructured":"McLean K, Monnat SM, Rigg K, Sterner GE, Verdery A. \u201cYou never know what you\u2019re getting\u201d: opioid users\u2019 perceptions of fentanyl in Southwest Pennsylvania. Subst Use Misuse. 2019;54:955\u201366.","journal-title":"Subst Use Misuse"},{"key":"924_CR44","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1080\/07853890.2022.2079149","volume":"54","author":"C Dun","year":"2022","unstructured":"Dun C, Allen ST, Latkin C, Knowlton A, Weir BW. The changing epidemiology of opioid overdose in Baltimore, Maryland, 2012\u20132017: insights from emergency medical services. Ann Med. 2022;54:1738\u201348.","journal-title":"Ann Med"},{"key":"924_CR45","first-page":"117","volume":"2018","author":"M Gilbert","year":"2019","unstructured":"Gilbert M. Transparency and corruption: a general analysis. Univ Chicago Legal Forum. 2019;2018:117\u201338.","journal-title":"Univ Chicago Legal Forum"},{"key":"924_CR46","unstructured":"State of Ohio Integrated Behavioral Health Dashboard [Internet]. Data Ohio. 2023. Available from: https:\/\/data.ohio.gov\/wps\/portal\/gov\/data\/view\/ohio-ibhd."},{"key":"924_CR47","unstructured":"The Columbus & Franklin County Addiction Plan [Internet]. Columbus Public Health. 2023. Available from: https:\/\/cfcap-columbus.hub.arcgis.com\/."},{"key":"924_CR48","first-page":"257","volume":"83","author":"N Dasgupta","year":"2022","unstructured":"Dasgupta N. History and future of harm reduction in North Carolina: pragmatism and innovation. N Carol Med J. 2022;83:257\u201360.","journal-title":"N Carol Med J"},{"key":"924_CR49","doi-asserted-by":"publisher","first-page":"e2118235118","DOI":"10.1073\/pnas.2118235118","volume":"118","author":"B Allen","year":"2021","unstructured":"Allen B, Feldman JM, Paone D. Public health and police: building ethical and equitable opioid responses. Proc Natl Acad Sci USA. 2021;118:e2118235118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"924_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drugpo.2016.12.005","volume":"42","author":"T Dickinson","year":"2017","unstructured":"Dickinson T. Non-violent threats and promises among closed-market drug dealers. Int J Drug Policy. 2017;42:7\u201314.","journal-title":"Int J Drug Policy"},{"key":"924_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.drugpo.2017.09.010","volume":"50","author":"AD Latimore","year":"2017","unstructured":"Latimore AD, Bergstein RS. \u201cCaught with a body\u201d yet protected by law? Calling 911 for opioid overdose in the context of the Good Samaritan Law. Int J Drug Policy. 2017;50:82\u20139.","journal-title":"Int J Drug Policy"},{"key":"924_CR52","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.addbeh.2017.06.006","volume":"74","author":"AE Rudolph","year":"2017","unstructured":"Rudolph AE, Young AM, Havens JR. A rural\/urban comparison of privacy and confidentiality concerns associated with providing sensitive location information in epidemiologic research involving persons who use drugs. Addict Behav. 2017;74:106\u201311.","journal-title":"Addict Behav"},{"key":"924_CR53","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2105\/AJPH.2019.305268","volume":"109","author":"CS Davis","year":"2019","unstructured":"Davis CS, Carr DH, Samuels EA. Paraphernalia laws, criminalizing possession and distribution of items used to consume illicit drugs, and injection-related harm. Am J Public Health. 2019;109:1564\u20137.","journal-title":"Am J Public Health"},{"key":"924_CR54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drugpo.2019.09.017","volume":"74","author":"JJ Palamar","year":"2019","unstructured":"Palamar JJ, Acosta P, Sutherland R, Shedlin MG, Barratt MJ. Adulterants and altruism: a qualitative investigation of \u201cdrug checkers\u201d in North America. Int J Drug Policy. 2019;74:160\u20139.","journal-title":"Int J Drug Policy"},{"key":"924_CR55","volume-title":"S.B. 288","author":"DM Papp","year":"2023","unstructured":"Papp DM, Maki SA. S.B. 288. Columbus: State of Ohio Legislature; 2023."},{"key":"924_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7517-6-16","volume":"6","author":"CS Davis","year":"2009","unstructured":"Davis CS, Beletsky L. Bundling occupational safety with harm reduction information as a feasible method for improving police receptiveness to syringe access programs: evidence from three U.S. cities. Harm Reduct J. 2009;6:1\u20138.","journal-title":"Harm Reduct J"},{"key":"924_CR57","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.2105\/AJPH.2015.302681","volume":"105","author":"L Beletsky","year":"2015","unstructured":"Beletsky L, Cochrane J, Sawyer AL, Serio-Chapman C, Smelyanskaya M, Han J, et al. Police encounters among needle exchange clients in Baltimore: drug law enforcement as a structural determinant of health. Am J Public Health. 2015;105:1872\u20139.","journal-title":"Am J Public Health"},{"key":"924_CR58","doi-asserted-by":"publisher","first-page":"103471","DOI":"10.1016\/j.drugpo.2021.103471","volume":"99","author":"A Greer","year":"2022","unstructured":"Greer A, Zakimi N, Butler A, Ferencz S. Simple possession as a \u2018tool\u2019: drug law enforcement practices among police officers in the context of depenalization in British Columbia, Canada. Int J Drug Policy. 2022;99:103471.","journal-title":"Int J Drug Policy"},{"key":"924_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40352-022-00172-y","volume":"10","author":"HM Smiley-McDonald","year":"2022","unstructured":"Smiley-McDonald HM, Attaway PR, Richardson NJ, Davidson PJ, Kral AH. Perspectives from law enforcement officers who respond to overdose calls for service and administer naloxone. Health Justice. 2022;10:1\u201313.","journal-title":"Health Justice"},{"key":"924_CR60","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/bjc\/39.4.488","volume":"39","author":"L Maher","year":"1999","unstructured":"Maher L, Dixon D. Policing and public health. Br J Criminol. 1999;39:488\u2013512.","journal-title":"Br J Criminol"},{"key":"924_CR61","unstructured":"Krawczyk N, Jordan A, Cerd\u00e1 M. Optimizing opioid settlement funds to save lives: investing in equitable solutions. Health Affairs Forefront. 2023;1\u201310."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00924-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00924-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00924-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:05:01Z","timestamp":1705158301000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00924-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00924-5","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}